
March 25 (Reuters) - Corcept Therapeutics shares jumped more than 32% to nearly a two-month high on Wednesday after the U.S. health regulator approved its lead drug for treating an aggressive form of ovarian cancer that no longer responds to standard treatment.
The U.S. Food and Drug Administration approved relacorilant, brand name Lifyorli, for use in combination with the chemotherapy drug nab-paclitaxel.
The therapy is cleared for adults with platinum-resistant epithelial ovarian cancer, a type that returns or progresses within about six months of platinum-based chemotherapy.
Lifyorli works by blocking cortisol-related stress signals in the body, a mechanism that can make cancer cells more responsive to chemotherapy.
The approval was based on a late-stage trial involving 381 patients. The data showed those treated with the combination lived a median of 16 months, compared with 11.9 months for patients receiving chemotherapy alone.
Patients are advised to take 150 mg of the drug on the day before, the day of, and the day after each infusion of nab-paclitaxel, the FDA said.
The treatment carries warnings for low white blood cell counts, serious infections, adrenal insufficiency and potential harm to unborn babies, and should not be used in patients who rely on steroid medications to survive.
UBS analyst Ashwani Verma viewed the approval, which came three months ahead of schedule, as a positive, but said a contraindication for patients on steroid medications could be a hurdle and estimated its peak sales of about $550 million.
In December, the FDA had declined to approve relacorilant for hypertension linked to Cushing's syndrome, saying the drug failed to outperform a placebo and raised concerns about potential liver injury — a setback that sent the company's shares plunging about 50%.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Devika Syamnath and Shilpi Majumdar)
LATEST POSTS
- 1
As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico - 2
Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead - 3
These four astronauts could soon travel farther from Earth than anyone has gone before - 4
Motivational Travel Objections for History Buffs - 5
Scientists document a death from a meat allergy tied to certain ticks
Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
Blue Origin’s New Glenn rocket landed its booster on a barge at sea – an achievement that will broaden the commercial spaceflight market
4 Coolers for Present day Kitchens
Make your choice for the PS5 game that you love playing with companions!
EU Council president: Ukraine should receive binding guarantees
Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
2024 Eurovision winner Nemo returns trophy over Israel's participation
Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
Figure out How to Pick the Right Toothbrush for You













